BLOG/πŸ‡ΊπŸ‡ΈUnited StatesΒ·Β·daily

All HHS Contracts β€” January 23, 2026

All HHS Contracts

5 total filings analysed

Executive Summary

HHS awarded $482M across 5 contracts in this period, with CMS dominating 78% ($357M) on IT/enrollment services signaling sustained healthcare IT modernization spend through 2026+. Three bullish signals highlight ~$421M in revenue visibility for IT/cloud and biodefense pharma contractors amid full obligation outlays averaging 58%. Neutral signals on nonprofit/long-term engineering limit equity upside despite $61M potential.

Tracking the trend? Catch up on the prior All HHS Contracts digest from January 21, 2026.

Investment Signals(3)

  • CMS IT sustainment ramp-up(HIGH)
    β–²

    CMS obligations total $327M (68% of stream) on enrollment/cloud services with $239M outlayed, favoring established IT players through 2026 extensions.

  • Biodefense pharma backlog(HIGH)
    β–²

    $125M firm-fixed non-competitive award to Elusys provides 4.7-year revenue at $17.7M outlayed, underscoring HHS preparedness priority.

  • Options exercise potential(MEDIUM)
    β–²

    $134M unexercised options across contracts (e.g., Samtek $44M ceiling, Yale $52M) could unlock 28% value uplift if triggered by 2026-2029.

Risk Flags(2)

  • Execution[HIGH RISK]
    β–Ό

    Long performance periods (avg. to 2027+, NIH to 2035) expose to budget cuts/delays, with low outlay progress in 40% of contracts (e.g., Elusys 14%, NORESCO 12%).

  • Competitive[MEDIUM RISK]
    β–Ό

    Full/open competition in 60% of awards to non-small/nonprofits signals vulnerability to rebids post-2026.

Opportunities(3)

  • β—†

    $116M remaining obligations (24% of total) through 2026+ for IT/pharma execution.

  • β—†

    CMS cloud/modernization focus ($38M Samtek) amid small biz set-asides positions minority IT firms for follow-ons.

  • β—†

    Non-competitive NIH engineering renewal potential post-2035 on $30M base.

Sector Themes(2)

  • β—†

    CMS captures 74% value on enrollment/cloud contracts, blending time/materials and fixed-price for predictable ~$70M+ tails.

  • β—†

    ASPR non-compete awards signal entrenched pharma procurement amid low outlay start.

Watch List(3)

  • πŸ‘

    {"entity"=>"Nighthawk Biosciences", "reason"=>"$125M Elusys award = 4.7yr visibility but 14% outlay flags revenue ramp risk.", "trigger"=>"Outlays >$30M by mid-2026"}

  • πŸ‘

    {"entity"=>"Cognosante MVH LLC", "reason"=>"Largest $258M CMS obligation with $70M tail through 2026 extensions.", "trigger"=>"Option exercise to $259M ceiling"}

  • πŸ‘

    {"entity"=>"CMS Cloud Solicitations", "reason"=>"Samtek $38M modernizes CCSQ; pattern for small biz IT scale-up.", "trigger"=>"New set-aside awards >$50M"}

Get daily alerts with 3 investment signals, 2 risk alerts, 3 opportunities and full AI analysis of all 5 filings

πŸ‡ΊπŸ‡Έ More from United States

View all β†’
All HHS Contracts β€” January 23, 2026 | Gunpowder Blog